Histotripsy plus chemo vs. chemo alone for advanced liver-only colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding histotripsy—a non-invasive ultrasound treatment that destroys liver tumors—to standard chemotherapy improves outcomes for people with advanced colorectal cancer that has spread to the liver. It may be an option if your cancer is mainly in the liver and you are starting or have recently had chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to your liver (and possibly small spots in your lungs, but not elsewhere).
- You are about to start, are within 3 months of starting, or have finished chemotherapy within the last month.
- You have at least one liver tumor that cannot be completely removed by surgery or ablation.
- You are age 18 or older.
- You are healthy enough to tolerate general anesthesia and do not have severe liver damage (Childs C cirrhosis).
- Your blood cell counts are adequate (WBC above 3,000 and neutrophils above 1,500).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether giving chemotherapy after surgery only for people whose blood test (ctDNA) shows no remaining cancer can help prevent the cancer from coming back. It is for people with colon cancer that has spread to the liver who had the tumor fully removed.
This trial tests whether giving chemotherapy directly into the liver after surgery can lower the chance of cancer coming back. It is for people who had multiple liver tumors removed and whose cancer did not grow during pre-surgery chemo.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests two procedures—irreversible electroporation and stereotactic body radiotherapy—for people whose colorectal cancer has spread to the liver (1–3 tumors near major blood vessels or bile ducts) and can't be surgically removed or treated with heat. The goal is to see if these approaches can safely destroy those hard-to-reach tumors.
This trial compares two treatments for liver cancer that can’t be removed with surgery: chemo through the liver (TACE) alone versus TACE plus a precise radiation treatment (SBRT). It may help people whose cancer stays in the liver but can’t be operated on, by testing whether adding focused radiation improves outcomes.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.